|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/22 | |
| A61P 11/00 | |||
| A61P 29/00 | |||
| A61P 1/04 | |||
| A61P 43/00 |
| (11) | Patento numeris | 3256150 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16714558.0 |
| Europos patento paraiškos padavimo data | 2016-02-04 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-12-20 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-12-09 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IT2016/000027 |
| Data | 2016-02-04 |
| (87) | Numeris | WO 2016/129005 |
| Data | 2016-08-18 |
| (30) | Numeris | Data | Šalis |
| RM20150056 | 2015-02-09 | IT | |
| UB20153089 | 2015-09-18 | IT |
| (72) |
ROMANI, Luigina, IT
GARACI, Enrico, IT
|
| (73) |
SciClone Pharmaceuticals International Ltd.,
PO Box 309 Ugland House, Grand Cayman KY-1-1104,
KY
|
| (54) | THYMOSIN ALPHA 1 FOR USE IN TREATMENT OF CYSTIC FIBROSIS |
| THYMOSIN ALPHA 1 FOR USE IN TREATMENT OF CYSTIC FIBROSIS |